#7

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		041673-2045	09/788,188
INFORMATION DISCLOSURE CITATION		APPLICANT	
		Mark Tuszynski	
(Use several sheets if necessary)		FILING DATE	GROUP ART UNIT
		02/16/2001	~~1653~~ 1632

OIPE JC
OCT 15 2001
PATENT & TRADEMARK OFFICE

RECEIVED
OCT 17 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
SNC	A1	4,338,397	07/06/1982		435	68	
	A2	4,757,013	07/12/1988		435	172.3	
	A3	5,169,762	12/08/1992		435	69.1	
	A4	5,235,043	08/10/1993		530	399	
	A5	5,364,769	11/15/1994		435	69.1	
	A6	5,488,099	01/30/1996		530	399	
	A7	5,608,036	03/04/1997		530	324	
SNC	A8	6,090,781	07/18/2000		514	12	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	A9	~~19911175976-A~~		Japan				
	A10	~~1993189770-A4~~		Japan				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

SNC	A11	Berkemeier, et al., "Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB," *Neuron*, 7:857-866 (1991)
	A12	Blesch, et al., "Ex Vivo Gene Therapy for Alzheimer's Disease and Spinal Cord Injury," *Clin. Neurosci.*, 3:268-274 (1996)
	A13	Bolivar, et al., "Construction and Characterization of New Cloning Vehicles," *Gene*, 2:95-113 (1977)
	A14	Dauber-Osguthorpe, et al., "Conformational analysis of peptide surrogates," *Int. J. Pep. Prot. Res.*, 38:357-377 (1991)
SNC	A15	Ernfors, et al., "Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: Developmental and topographical expression in the brain," *Proc. Natl. Acad. Sci. USA*, 87:5454-5458 (1990)

EXAMINER	DATE CONSIDERED
Shin-Lin Chen	6-11-03

* **EXAMINER: Initial if citation considered, whether r not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 041673-2045	SERIAL NO. 09/788,188
	INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	APPLICANT Mark Tuszynski	
		FILING DATE 02/16/2001	GROUP ART UNIT 1632 ~~1653~~

OIPE JC87 OCT 15 2001 PATENT AND TRADEMARK OFFICE

RECEIVED OCT 17 2001 TECH CENTER 1600/2900

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A16	Guichard, et al., "Synthesis and Antigenic Properties of Reduced Peptide Bond Pseudopeptide Analogues of a Histone H3 Hexapeptide," *Peptide Research*, 7:308-321 (1994)
	A17	Gutierrez, et al., "A peptide that mimics the carboxy-terminal domain of SNAP-25 blocks Ca^{2+} - dependent Exocytosis in chromaffin cells," *FEBS Letters*, 372:39-43 (1995)
	A18	Hallböök, et al., "Evolutionary Studies of the Nerve Growth Factor Family Reveal a Novel Member Abundantly Expressed in Xenopus Ovary," *Neuron*, 6:845-858 (1991)
	A19	Hefti, et al., "Nerve Growth Factor and Alzheimer's Disease," *Ann Neurol.*, 20:275-281 (1986)
	A20	Hess, et al., "Cooperation of Glycolytic Enzymes," *J. Adv. Enzyme Reg.*, 7:149-167 (1968)
	A21	Heymach, et al., "The Regulated Secretion and Vectorial Targeting of Neurotrophins in Neuroendocrine and Epithelial Cells," *J. Biol. Chem.*, 271:25430-25437 (1996)
	A22	Hitzeman, et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (*PGK*) by an Immunological Screening Technique," *J. Biol. Chem.*, 255:2073 (1980)
	A23	Hohn, et al., "Identification and characterization of a novel member of the nerve growth factor/brain-derived Neurotrophic factor family," *Nature*, 344:339 (1990)
	A24	Holland, et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase," *Biochemistry*, 17:4900 (1978)
	A25	Ip, et al., "Mammalian neurotrophin-4: Structure, chromosomal locatlization, tissue distribution, and receptor specificity," *Proc. Natl. Acad. Sci. USA*, 89:3060-3064 (1992)
	A26	Jones, et al., "Molecular cloning of a umna gene that is a member of the nerve growth factor family," *Proc. Natl. Acad. Sci. USA*, 87:8060-8064 (1990)
	A27	Kaisho, et al., "Cloning and expression of a cDNA encoding a novel human neurotrophic factor," *FEBS Lett.*, 266:187 (1990)
	A28	King, et al., "Structure-Immunogenicity Relationship of Melittin, Its Transposed Analogues, and D-Melittin," *J. Immunol.*, 153:1124-1131 (1994)
	A29	Leibrock, et al., "Molecular cloning and expression of brain-derived neurotrophic factor," *Letters to Nature*, 341:149-152 (1989)
	A30	Maisonpierre, et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF," *Science*, 24:1446-1451 (1990)

Shin-Lin Chen 6-1-03

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 041673-2045	SERIAL NO. 09/788,188
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Mark Tuszynski	
		FILING DATE 02/16/2001	GROUP ART UNIT ~~1653~~ 1632

OIPE JC87 OCT 15 2001 PATENT & TRADEMARK OFFICE

RECEIVED OCT 17 2001 TECH CENTER 1600/2900

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A31	Merrifield, et al., "Design and synthesis of antimicrobial peptides," *Ciba Foundation Symposium*, 186:5-20 (1994)
	A32	Meyer, et al., "Synthesis Using a Fmoc-Based Strategy and Biological Activities of Some Reduced Peptide Bond Pseudopeptide Analogues of Dynorphin A[1]," *J. Med. Chem.*, 38:3462-3468 (1995)
	A33	Rosenthal, et al., "Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor," *Neuron*, 4:767 (1990)
	A34	Stewart, et al., "Laboratory Techniques in Solid Phase Peptides Synthesis," *Freeman*, San Francisco, pp. 27-35 (1969)
	A35	Tuszynski, et al., "Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration," *Gene Therapy*, 3:305-314 (1996)
	A36	Tuszynski, et al., "Recombinant Human Nerve Growth Factor Infusions Prevent Cholinergic Neuronal Degeneration in the Adult Primate Brain," *Ann. Neurol.*, 30:625-636 (1991)
	A37	Ullrich, "Human β-nerve growth factor gene sequence highly homologous to that of mouse," *Nature*, 303:821-825 (1983)
	A38	Urfer, et al., "The binding epitopes of neurotrophin-3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin," *EMBO J.*, 13(24):5896-909 (1994)
	A39	Wade, et al., "All-D amino acid-containing channel-forming antibiotic peptides," *Proc. Natl. Acad. Sci. USA*, 87:4761-4765 (1990)
	A40	Whittemore, et al., "Rat β-Nerve Growth Factor Sequence and Site of Synthesis in the adult Hippocampus," *J. Neuro. Res.*, 20:403-410 (1988)

Shin-Lin Chen 6-11-03

OIPE FEB 25 2003 PATENT & TRADEMARK OFFICE

#12

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/788,188
Filing Date	02/16/2001
First Named Inventor	Mark Tuszynski
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	041673-2045

RECEIVED FEB 28 2003 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
SLC	A1	Linden and Kaushansky, "The Glycan Domain of Thrombopoietin Enhances Its Secretion." Biochemistry, 39:3044-3051, 2000.	
SLC	A2	Seidah et al., "Cellular Processing of the Nerve Growth Factor Precursor by the Mammalian Pro-Protein Convertases." Biochemistry Journal, 314: 951-960, 1996.	

Examiner Signature	Shin-Lin Chen	Date Considered	6-11-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.